Folks if you have not bought HOLX yet please do. Big news today--The company’s test is called Panther Fusion SARS-CoV-2. “Hologic’s assay is the first widely available, high-throughput molecular diagnostic test specifically authorized for screening asymptomatic people,” the company said in a statement. FDA grants for asymptomatic- that's a large target audience this should be getting a better up 10% sort of move you are getting a gift!
Here Stoney, take a break from high flying biotechs and read this this AM. https://www.jud.ct.gov/lawlib/Notebooks/Pathfinders/Encroachment.pdf $WORK nipping at $28
ALLY Continues to looks strong) Have not purchased yet... Ally Financial Inc. (ALLY) NYSE - Nasdaq Real Time Price. Currency in USD Add to watchlist 25.03+0.53 (+2.16%) As of 9:43AM EDT. Market open.
Thanks Van I am aware of most of that stuff especially-- Defenses—Good faith belief as to nonexistence of encroachment—Excessive hardship to defendant caused by injunctive relief—No irreparable injury suffered by plaintiff/// But did you know a lot of this is a no go when one of the parties is non profit? I found this little loophole...
Send their lawyers an email: Dear Esteemed Esquire, You'll be glad to know I started moving the heavy stones on the grotto today, however shortly after I started I'm afraid I threw my back out. I considered going to the ER because I've never had back problems before, but I decided to take two Allieves and lay down and see if the pain goes away. I know you want that grotto moved asap by the threatening tone of your emails to date, so I'll be back out there tomorrow hopefully. Right now I'm in too much pain but I'm sure it will go away. Yours Truly, Stoney. Then ignore their emails for a month or so.
I like where you are going Van I was thinking the same thing. At the very least I send a letter saying I attempted to move the first stone and hurt myself and cannot do this until next spring. After all this has dragged out to a period of time when the earth will soon start getting hard. You know I really think I would win the case in a fair hearing but I understand one of the people at the land trust has a relative on the town board that would look at this.... One other thing they tied a ribbon to a dogwood tree I planted in memory of my dead mother...There's a big vase there & some chimes they want me to move-- I'm going to let them know about that in my next email... I planted these trees! My mother's ashes! -- Lets see them send one of their corporate responses tho that! Van did you buy FLDM-? Testing play? Fluidigm says funding for NIH project for COVID-19 tests increased by $22M --BAM!07:46 FLDM In a regulatory filing, Fluidigm said: "As previously disclosed in its Quarterly Report on Form 10-Q filed August 7, 2020, Fluidigm Corporation entered into a letter contract in July 2020 with the National Institutes of Health - NIH - for a project under the NIH Rapid Acceleration of Diagnostics - RADx - program aimed at increasing the number, type, and availability of tests for SARS-CoV-2, the virus that causes COVID-19. On September 28, 2020, the company executed a definitive contract with the NIH as an amendment to the letter contract to expand production capacity and throughput capabilities for COVID-19 testing with Fluidigm microfluidics technology. Pursuant to the terms of the definitive contract, the funding for the project was increased by approximately $22.0M, for a total contract value of up to approximately $34.0M upon the achievement of milestones. The project will be funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, NIH, Department of Health and Human Services, under Contract No. 75N92020C0009. The contract contains a number of terms and conditions that are customary for government contracts of this nature, including, but not limited to, provisions giving the government the right to terminate the contract or to order the company to stop all or any part of the work under the contract for the government's sole convenience."
PIPELINE NEWS-- BioCryst resumed with an Overweight at JPMorgan 06:09 BCRX JPMorgan analyst Jessica Fye resumed coverage of BioCryst with an Overweight rating and $7 price target. The analyst sees BioCryst's "soon-to-be-approved" Orladeyo for hereditary angioedema prophylaxis as an underappreciated value driver.
Utz Brands to purchase H.K. Anderson assets from Conagra HK appears to be mostly pretzels... https://www.hk-anderson.com/baked-pretzel-products
Inovio vaccine delay 'disappointing, but understandable,' says Benchmark 07:15 INO Benchmark analyst Aydin Huseynov lowered the firm's price target on Inovio to $25 from $36 after the company reported that its Phase 2/3 trial for its COVID-19 vaccine candidate has been put on partial clinical hold as the FDA has more questions about INO-4800 and the CELLECTRA device. While the delay is "disappointing," he views it as understandable and thinks the additional front-end data requests may actually strengthen the Phase 2/3 readout when data is eventually available, said Huseynov, who keeps a Buy rating on Inovio shares.
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target 16:20 ZNTL Cantor Fitzgerald analyst Eliana Merle initiated coverage of Zentalis Pharmaceuticals with an Overweight rating and $44 price target. The analyst sees "long-term underappreciated value potential" from the company's oncology portfolio. Zentalis has an internal drug discovery engine and currently four clinical-stage targeted oncology assets, all developed in-house, Merle tells investors in a research note. The analyst believes the assets have $1B-plus revenue potential and sees "many sources of potential upside" over the next 12-24 months for the shares.